JP Morgan 2022 – day one sees healthy deal flow from biopharma
But transactions are small, and mostly involve licensing rather than takeouts, with cancer and gene editing featuring heavily.
Big beasts drive biopharma valuations higher in 2021
A handful of huge success stories mask disappointing performances elsewhere, with small caps and Asian pharma firms feeling the pain.
Free to download now: Evaluate Vantage’s 2022 Preview
Explore what might be in store for biopharma next year in our new report, with new data analyses, catalyst tables and investor interviews.
Bavarian Nordic goes it alone, for now
Phase 3 in RSV will begin without a partner, while decent Covid-19 booster data pave the way for pivotal development.
Novo’s $3.3bn GalXC quest
The usually conservative group spends big on Dicerna – but others might be interested too.
RSVVW 2021 – Pfizer gets maternal
Positive phase 2 data with the group’s maternal RSV vaccine set up a busy 2022 for work on the infectious disease.
Vertex goes small with Mammoth deal
Vertex strikes yet another gene editing deal, this time with the “ultra-small” Crispr specialist Mammoth.
